Scottish Medicines Consortium crizotinib 200mg and 250mg hard capsules (Xalkori)

following a full submission assessed under the ultra-orphan medicine process:

crizotinib (Xalkori®) is accepted for use within NHSScotland.

Indication under review: treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC).

In a small, single arm, open-label, phase I study of patients with advanced ROS1-positive NSCLC, treatment with crizotinib resulted in an objective response in 70% of patients.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of crizotinib. This advice is contingent upon the continuing availability of the PAS in NHSScotland or a list price that is equivalent or lower.

This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.


To read more Press Release articles, click here.